Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412234 | 0.86 | RAB9A (0.44) | RAB9ALMNAMAPK1HTTCA12 | |
| SCHEMBL8262561 | 0.86 | RAB9A (0.42) | RAB9ALMNAMAPK1HTTCA9 | |
| SCHEMBL24923 | 0.86 | RAB9A (0.42) | RAB9ALMNAMAPK1HTTALDH1A1 | |
| SCHEMBL202632 | 0.84 | POLB (0.46) | RAB9ALMNAMAPK1HTTALDH1A1 | |
| SCHEMBL201405 | 0.81 | LMNA (0.53) | RAB9ALMNAMAPK1HTTCA12 | |
| SCHEMBL29792549 | 0.81 | LMNA (0.53) | RAB9ALMNAMAPK1HTTCA12 | |
| SCHEMBL8564952 | 0.81 | ALDH1A1 (0.61) | RAB9ALMNAMAPK1HTTCA12 | |
| SCHEMBL24717393 | 0.80 | RAB9A (0.51) | RAB9ALMNAMAPK1HTTCA12 | |
| SCHEMBL4501917 | 0.80 | HTT (0.51) | RAB9ALMNAMAPK1HTTCA12 | |
| SCHEMBL22993287 | 0.79 | CA12 (0.48) | RAB9ALMNAMAPK1HTTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3820864-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | Blade Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112703188-A | Method for treating liver fibrosis using calpain inhibitor | 布莱德治疗公司 | 2021-04-23 | — | — | CN | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20190307766-A1 | CYCLIC AMINES | MINDIMMUNE THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3536689-A1 | 2-(CYCLIC AMINEETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS | MindImmune Therapeutics, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-1853600-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S | Astex Therapeutics Limited (GB) | 2007-11-14 | — | — | EP | disclosed |
| EP-1846395-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2006077419-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077419-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPN1, CAPNS1, CAPN2 | RAB9A 2693/4885LMNA 663/4885MAPK1 2688/4885 |
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | RAB9A 2764/4885LMNA 829/4885MAPK1 3657/4885 |
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | RAB9A 3575/4885LMNA 2809/4885MAPK1 91/4885 |
| US-20190307766-A1 | CYCLIC AMINES | P2RX7, ADORA2A, P2RX2 | RAB9A 2943/4885LMNA 2464/4885MAPK1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.